Cargando…
Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020
BACKGROUND: In order to estimate the prevalence and understand the spread of SARS-CoV-2 in Sweden, the Public Health Agency of Sweden, with support from the Swedish Armed Forces, conducted a series of point prevalence surveys between March and December 2020. METHODS: Sampling material and instructio...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672540/ https://www.ncbi.nlm.nih.gov/pubmed/36396981 http://dx.doi.org/10.1186/s12879-022-07858-6 |
_version_ | 1784832758544072704 |
---|---|
author | Groenheit, Ramona Beser, Jessica Kühlmann Berenzon, Sharon Galanis, Ilias van Straten, Edward Duracz, Jan Rapp, Marie Hansson, Disa Mansjö, Mikael Söderholm, Sandra Muradrasoli, Shaman Risberg, Anna Ölund, Richard Wiklund, Andreas Metzkes, Kristoffer Lundberg, Matilda Bacchus, Philip Tegmark Wisell, Karin Bråve, Andreas |
author_facet | Groenheit, Ramona Beser, Jessica Kühlmann Berenzon, Sharon Galanis, Ilias van Straten, Edward Duracz, Jan Rapp, Marie Hansson, Disa Mansjö, Mikael Söderholm, Sandra Muradrasoli, Shaman Risberg, Anna Ölund, Richard Wiklund, Andreas Metzkes, Kristoffer Lundberg, Matilda Bacchus, Philip Tegmark Wisell, Karin Bråve, Andreas |
author_sort | Groenheit, Ramona |
collection | PubMed |
description | BACKGROUND: In order to estimate the prevalence and understand the spread of SARS-CoV-2 in Sweden, the Public Health Agency of Sweden, with support from the Swedish Armed Forces, conducted a series of point prevalence surveys between March and December 2020. METHODS: Sampling material and instructions on how to perform self-sampling of the upper respiratory tract were delivered to the homes of the participants. Samples were analysed by real-time PCR, and the participants completed questionnaires regarding symptoms. FINDINGS: The first survey in the Stockholm region in March 2020 included 707 participants and showed a SARS-CoV-2 prevalence of 2.5%. The following five surveys, performed on a national level, with between 2461 and 2983 participants, showed SARS-CoV-2 prevalences of 0.9% (April), 0.3% (May), 0.0% (August), 0.0% (September), and 0.7% (December). All positive cases who responded to questionnaires reported experiencing symptoms that occurred from 2 weeks before the date of sampling up to and including the date of sampling. INTERPRETATION: None of the individuals shown to be PCR-positive were asymptomatic at the time of sampling or in the 14 days prior to sampling. This is in contrast to many other surveys in which a substantial proportion of positive cases have been reported to be asymptomatic. Our surveys demonstrate a decreasing ratio between notified cases and the observed prevalence throughout the year, in line with increasing testing capacity and the consecutive inclusion of all symptomatic individuals in the case definition for testing. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07858-6. |
format | Online Article Text |
id | pubmed-9672540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96725402022-11-18 Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 Groenheit, Ramona Beser, Jessica Kühlmann Berenzon, Sharon Galanis, Ilias van Straten, Edward Duracz, Jan Rapp, Marie Hansson, Disa Mansjö, Mikael Söderholm, Sandra Muradrasoli, Shaman Risberg, Anna Ölund, Richard Wiklund, Andreas Metzkes, Kristoffer Lundberg, Matilda Bacchus, Philip Tegmark Wisell, Karin Bråve, Andreas BMC Infect Dis Research BACKGROUND: In order to estimate the prevalence and understand the spread of SARS-CoV-2 in Sweden, the Public Health Agency of Sweden, with support from the Swedish Armed Forces, conducted a series of point prevalence surveys between March and December 2020. METHODS: Sampling material and instructions on how to perform self-sampling of the upper respiratory tract were delivered to the homes of the participants. Samples were analysed by real-time PCR, and the participants completed questionnaires regarding symptoms. FINDINGS: The first survey in the Stockholm region in March 2020 included 707 participants and showed a SARS-CoV-2 prevalence of 2.5%. The following five surveys, performed on a national level, with between 2461 and 2983 participants, showed SARS-CoV-2 prevalences of 0.9% (April), 0.3% (May), 0.0% (August), 0.0% (September), and 0.7% (December). All positive cases who responded to questionnaires reported experiencing symptoms that occurred from 2 weeks before the date of sampling up to and including the date of sampling. INTERPRETATION: None of the individuals shown to be PCR-positive were asymptomatic at the time of sampling or in the 14 days prior to sampling. This is in contrast to many other surveys in which a substantial proportion of positive cases have been reported to be asymptomatic. Our surveys demonstrate a decreasing ratio between notified cases and the observed prevalence throughout the year, in line with increasing testing capacity and the consecutive inclusion of all symptomatic individuals in the case definition for testing. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07858-6. BioMed Central 2022-11-17 /pmc/articles/PMC9672540/ /pubmed/36396981 http://dx.doi.org/10.1186/s12879-022-07858-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Groenheit, Ramona Beser, Jessica Kühlmann Berenzon, Sharon Galanis, Ilias van Straten, Edward Duracz, Jan Rapp, Marie Hansson, Disa Mansjö, Mikael Söderholm, Sandra Muradrasoli, Shaman Risberg, Anna Ölund, Richard Wiklund, Andreas Metzkes, Kristoffer Lundberg, Matilda Bacchus, Philip Tegmark Wisell, Karin Bråve, Andreas Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title | Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title_full | Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title_fullStr | Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title_full_unstemmed | Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title_short | Point prevalence of SARS-CoV-2 infection in Sweden at six time points during 2020 |
title_sort | point prevalence of sars-cov-2 infection in sweden at six time points during 2020 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672540/ https://www.ncbi.nlm.nih.gov/pubmed/36396981 http://dx.doi.org/10.1186/s12879-022-07858-6 |
work_keys_str_mv | AT groenheitramona pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT beserjessica pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT kuhlmannberenzonsharon pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT galanisilias pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT vanstratenedward pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT duraczjan pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT rappmarie pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT hanssondisa pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT mansjomikael pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT soderholmsandra pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT muradrasolishaman pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT risberganna pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT olundrichard pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT wiklundandreas pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT metzkeskristoffer pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT lundbergmatilda pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT bacchusphilip pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT tegmarkwisellkarin pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 AT braveandreas pointprevalenceofsarscov2infectioninswedenatsixtimepointsduring2020 |